ScandTick Innovation

ScandTick Innovation is a Swedish biotechnology company dedicated to the development of a human vaccine against Lyme borreliosis (Lyme disease). Based in Kalmar, the company leverages research originating from Linköping University and clinical expertise from the Tick-borne Diseases Clinic at Kalmar County Hospital. Their lead program is a recombinant protein vaccine designed to provide broad protection against the multiple Borrelia species prevalent in Europe and North America. ScandTick aims to address a significant global health gap, as there is currently no widely available human vaccine for Lyme disease. The company operates within a collaborative network of academic and clinical partners to advance its candidates through the pre-clinical pipeline.